Barzman, D; Ni, Y; Griffey, M; Bachtel, A; Lin, K; Jackson, H; Sorter, M; DelBello, M. Automated Risk Assessment for School Violence a Pilot Study. Psychiatric Quarterly. 2018; 89(4):817-828.
This study evaluated students using a more standard and sensitive method to help identify students who are at high risk for school violence. 103 participants were recruited through Cincinnati Children's Hospital Medical Center from psychiatry outpatient clinics, the inpatient units, and the emergency department. The novel machine learning algorithm was highly accurate in assessing school violence risk and achieved an AUC of 91.02% when using the interview content to predict risk of school violence, and the AUC increased to 91.45% when demographic and socioeconomic data were added.
Ramsey, LB; Prows, CA; Zhang, K; Saldana, SN; Sorter, MT; Pestian, JP; Wenstrup, RJ; Vinks, AA; Glauser, TA. Implementation of Pharmacogenetics at Cincinnati Childrens Hospital Medical Center Lessons Learned Over 14 Years of Personalizing Medicine. Clinical Pharmacology and Therapeutics. 2019; 105(1):49-52.
Pharmacogenetics is an important step in personalizing medicine. There is great variability in medication response that can result in poor results or adverse reactions. Understanding the role of genetics and pharmacokinetic variability show great promise in improving drug selection and dosing for an increasing number of conditions. This paper describes the development of a genetic pharmacology service in a large pediatric hospital that can serve as a model to assist other care systems. The implementation of testing processes and future developments and contributions of a pharmacogenetics program is illustrated so that others are able to develop this important service to improve and individualize care.
Shaffer, RC; Wink, LK; Ruberg, J; Pittenger, A; Adams, R; Sorter, M; Manning, P; Erickson, CA. Emotion Regulation Intensive Outpatient Programming Development, Feasibility, and Acceptability. Journal of Autism and Developmental Disorders. 2019; 49(2):495-508.
This publication details the development of an intensive outpatient program to address emotion regulation in youth ages 8-12 with ASD and other neurodevelopmental disorders. A chart review was conducted including participants who completed the clinical program during the first several years of its development. Results demonstrated that the program was feasible to implement and that families were very satisfied with the program. Initial pilot outcomes indicated children significantly improved on standardized scales related to emotion regulation. This publication bridges a gap between clinical care, outcome measurement, and intervention research and it was pivotal in obtaining funding for a research trial of the program.
Hong, MP; Eckert, EM; Pedapati, EV; Shaffer, RC; Dominick, KC; Wink, LK; Sweeney, JA; Erickson, CA. Differentiating social preference and social anxiety phenotypes in fragile X syndrome using an eye gaze analysis a pilot study. Journal of Neurodevelopmental Disorders. 2019; 11(1).
This is the first manuscript to quantify difference in gaze patterns between persons with fragile X syndrome, a common genetic cause of autism, and idiopathic autism or autism of unknown cause. Persons with fragile X were shown to maintain preference for social viewing when given a choice to view social or non-social scenes, a preference not maintained by persons with idiopathic autism. Persons with fragile X, though, exhibited significantly reduced looking at the eye when viewing up close faces, a finding consistent with social anxiety. This research indicates that despite the overlap between fragile X and autism, the social deficits in fragile X may be more characterized as social anxiety versus a lack of social interest more characteristic of classic non-syndromic autism.
Erickson, CA; Kaufmann, WE; Budimirovic, DB; Lachiewicz, A; Haas-Givler, B; Miller, RM; Weber, JD; Abbeduto, L; Hessl, D; Hagerman, RJ; Berry-Kravis, E. Best Practices in Fragile X Syndrome Treatment Development. Brain Sciences. 2018; 8(12).
This paper outlines the thoughts of leaders and family stakeholders in the fragile X field regarding responding to past clinical trial failures to guide new novel approaches to treatment in the field. These recommendations hold promise to in the future reduce the high failure rate of clinical treatment in fragile X syndrome. Recommendations include use of quantitative outcome measures and use of small first in fragile X studies to best develop early on in study approaches to better ensure the success of subsequent large-scale multi-site projects.